Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered offering of common stock by Seattle Genetics, Inc. for gross proceeds of $575 million.
Seattle Genetics is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Bryan M. Quinn, Daniel Fox and Kimberly Wang. Partner Mario J. Verdolini and associate Eitan Ulmer provided tax advice. Partner Frank J. Azzopardi and associate Jesse L. Hallock provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.